Skip to main content

Beckman Coulter Life Sciences Launches Vi-CELL BLU 2.0 Software to Advance Data Integrity and GMP Readiness in Cell Analysis

Next-generation upgrade strengthens data comparability and compliance—without changing trusted instrumentation

Brought to you byBeckman Coulter
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00

Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, today announced the launch of Vi-CELL BLU 2.0 Viability Analyzer Software, a major upgrade that enables laboratories to modernize cell viability workflows while maintaining data continuity, compliance and operational confidence.

The new software supports laboratories in solving complex cell analysis challenges and accelerating the transition from research to biomanufacturing.

Built on the trusted Vi-CELL BLU instrument, the Vi-CELL BLU 2.0 Viability Analyzer Software delivers enhanced data comparability, integrity and uptime—enabling R&D and manufacturing teams to modernize workflows without disrupting established processes.

By offering improved cell counting algorithms and configurable analysis settings designed to align results with legacy instruments, supported by validated software documentation and application guidance, Vi-CELL BLU 2.0 Software helps labs avoid the complexity of an equipment transition.

“Vi-CELL BLU 2.0 Viability Analyzer Software was developed to help laboratories modernize cell analysis workflows without compromising data integrity or compliance,” said Dave Kremer, Senior Director Cell Health and Centrifugation at Beckman Coulter Life Sciences. “By aligning results with legacy systems while introducing advanced data controls, we’re enabling customers to accelerate adoption with confidence and reduce risk during transition.”

Additional enhancements include role-based access controls, electronic signatures, audit trails and traceability features to support regulated workflows and streamline integration into GMP environments, ensure consistency across projects, users and sites.

This advancement reflects Beckman Coulter Life Sciences commitment to accelerating scientific innovation and enabling more reliable, scalable cell analysis across the biopharma workflow.

Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
From Pilot to Practice: Advancing Regulatory Reliance

From Pilot to Precedent: A Year of Regulatory Innovation through PRISM and What it Means for Cloud Adoption in Regulatory Submissions

DNAnexus
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Improving Western Blot Analysis of Biofluid Samples

Improving Western Blot Analysis of Biofluid Samples

Bio-Rad
Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter

Products

Sino Biological Logo

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Illustrated floating metabolites and molecules

Metabolon Verus™ Kit: Metabolomics Profiling Kit

Metabolon
Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics